Vertex Pharmaceuticals Released Inaxaplin Clinical Results
New clinical data shows inaxaplin reduced proteinuria levels in patients with APOL1-mediated kidney disease.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you trust that emerging medical treatments will soon solve currently untreatable chronic conditions?
Vertex Pharmaceuticals has released Phase 2b clinical trial results for inaxaplin, showing the drug reduced key indicators of kidney damage. The treatment targets the underlying cause of APOL1-mediated kidney disease, for which there are currently no approved therapies.
Why it matters
This development is significant because approximately 150,000 people in the US and Europe suffer from APOL1-mediated kidney disease without access to dedicated treatments. The trial results offer a potential path toward the first approved therapeutic option for these patients.
The study administered a 45 mg once-daily dose of inaxaplin to 41 participants over 13 weeks. Data showed a 42.7% reduction in UACR for the modest proteinuria cohort and a 17.3% reduction for those with type 2 diabetes.
The players
Vertex Pharmaceuticals
This global biotechnology company specializes in developing and commercializing innovative medicines for serious human diseases.
The details
The Phase 2b AMPLIFIED study evaluated the drug's impact on kidney function in patients with APOL1-mediated kidney disease. Researchers reported no serious adverse events related to the treatment, with minor side effects including headaches in 7.3% of participants.
Timeline
Patients were evaluated at the Week 13 milestone for primary endpoint reductions.
Interim results for the ongoing Phase 2/3 AMPLITUDE trial are expected in early 2027.
The Tech Race
The development of inaxaplin represents a shift toward precision medicine that targets the genetic drivers of chronic conditions rather than just symptoms. This positions Vertex Pharmaceuticals as a leader in the race to provide the first specialized intervention for APOL1-mediated kidney disease.
Patients currently living with APOL1-mediated kidney disease may gain access to the first dedicated therapy if future trial phases confirm these findings. This could fundamentally change long-term treatment routines by addressing the disease's root cause rather than relying on general care.
The takeaway
The successful Phase 2b results provide a promising proof of concept for gene-targeted kidney disease therapies. Patients and their medical providers should monitor the upcoming 2027 interim trial data as a critical indicator for potential market availability.
What happens next
Vertex Pharmaceuticals has completed enrollment for the Phase 2/3 AMPLITUDE trial, with interim results anticipated in early 2027 that could support accelerated regulatory approval in the United States.
Further reading
Learn more about the latest developments in the Biotech sector.
Live Poll
Do you trust that emerging medical treatments will soon solve currently untreatable chronic conditions?
